In Beijing, Shanghai, and Hong Kong, we connected the CEOs of biopharma, diagnostic and medical device companies with government officials, institutional investors and potential partners.
Conscious Capital® Delegation Visit Greater China 2018 provided insights into operating throughout China and U.S. – China relations, as well as the opportunity to explore potential investment and cross-border partnering opportunities.
According to the World Health Organization, the population of individuals aged 60 or older is set to rise 90% in China to 240 million by 2020. Over this period, the healthcare sector in China will become a US$1 trillion a year business.
The Chinese market is developing rapidly, with technological breakthroughs that are driving innovation and an aggressive move towards cross-border collaboration, both for investments and licensing.
Ahead of the delegation visit, Conscious Capital® curated one-on-one and group meetings based upon targeted objectives and designed to facilitate a variety of different partnering mechanisms for co-development and/or investment.
With a targeted approach and sustained investor engagement, entry into Greater China can be transformational.
